Pazopanib

Catalog No.S3012 Synonyms: GW786034

Pazopanib Chemical Structure

Molecular Weight(MW): 437.52

Pazopanib is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFR, FGFR, c-Kit and c-Fms with IC50 of 10 nM, 30 nM, 47 nM, 84 nM, 74 nM, 140 nM and 146 nM in cell-free assays, respectively.

Size Price Stock Quantity  
USD 70 In stock
USD 210 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 11 Publications

5 Customer Reviews

  • Three RCC cell lines treated with different concentrations of TKI and HDIL-2 and incubated for 48 h. Microscopic images show apoptotic materials 48 h following treatment (arrows show the apoptotic materials in the pazopanib-treated cells).

    Expert Opin Pharmacother 2014 15(11), 1489-99. Pazopanib purchased from Selleck.

    J Virol 2011 85(5), 2296-303. Pazopanib purchased from Selleck.

  • Arch Toxicol, 2018, 92(4):1435-1451. Pazopanib purchased from Selleck.

    (a,b) Effect of Pazopanib on vascular network integrity. VMOs were exposed to drug from day 4 to 6. Data are normalized to day of first drug exposure and are shown as percentage of control. Error bars show mean ± s.d (n = 3) (p < 0.05 vs control).

    Sci Rep, 2016, 6:31589. Pazopanib purchased from Selleck.

  • (B) The effects of AZD2014, BEZ235, lapatinib, LEE011, pazopanib on PI3K/AKT signaling in sarcoma PDC line were determined by immunoblotting analysis. Cells were treated with 1 μM of the indicated drugs for 72 h.

    Transl Oncol, 2016, 9(3):197-202. Pazopanib purchased from Selleck.

Purity & Quality Control

Choose Selective VEGFR Inhibitors

Biological Activity

Description Pazopanib is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFR, FGFR, c-Kit and c-Fms with IC50 of 10 nM, 30 nM, 47 nM, 84 nM, 74 nM, 140 nM and 146 nM in cell-free assays, respectively.
Targets
VEGFR1 [1]
(Cell-free assay)
VEGFR2 [1]
(Cell-free assay)
VEGFR3 [1]
(Cell-free assay)
c-Kit [1]
(Cell-free assay)
PDGFR [1]
(Cell-free assay)
10 nM 30 nM 47 nM 74 nM 84 nM
In vitro

Pazopanib potently inhibits VEGF-induced phosphorylation of VEGFR2 in HUVEC cells with IC50 of 8 nM. [1] PPazopanib shows dose-dependent growth inhibition in all synovial sarcoma cell lines including SYO-1 and HS-SY-II cells. Proliferation of SYO-1 and HS-SY-II cells is inhibited even at 1 µg/mL of Pazopanib and is completely abolished at 5 µg/mL. Pazopanib induces G1 arrest, and thereby suppresses the growth of synovial sarcoma cells. Phosphorylation of Akts, GSK-3β, JNKs, p70 S6 Kinase, and mTOR is suppressed in Pazopanib-treated SYO-1 cells compared with that in the vehicle-treated cells. [2] Pazopanib between 20 m g/mL and 22.5 m g/mL shows an increasing reduction of RPE cell viability. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
human EoL-1-cell cell Mn3CS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NVLw[WkyUW6qaXLpeIlwdiCxZjDoeY1idiCHb1ytNU1k\WyuIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJIlkPTB;Mj64PYUuODVizszN NIDmfG9USU6JRWK=
human AN3-CA cell NHHqV5hIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NW\zd3V3UW6qaXLpeIlwdiCxZjDoeY1idiCDTkOtR2Eh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0yOC5yNTDuUS=> Ml31V2FPT0WU
human CGTH-W-1 cell NGDDeJRIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MW\Jcohq[mm2aX;uJI9nKGi3bXHuJGNIXEhvVz2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OFAvODFibl2= NF7DXppUSU6JRWK=
human GDM-1 cell MmXBS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NU\5R2hsUW6qaXLpeIlwdiCxZjDoeY1idiCJRF2tNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVExOy57OTDuUS=> MlzFV2FPT0WU
human A204 cell NEjjPJlIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MmHITY5pcWKrdHnvckBw\iCqdX3hckBCOjB2IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MUC5MlA3KG6P MWXTRW5ITVJ?
human G-402 cell MmO1S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NUHuTnI1UW6qaXLpeIlwdiCxZjDoeY1idiCJLUSwNkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVU{OS56NDDuUS=> NESwWpVUSU6JRWK=
human MFE-296 cell MnLVS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NF3VfHFKdmirYnn0bY9vKG:oIHj1cYFvKE2IRT2yPVYh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjV7MEKyJO69VQ>? NIn5bHNUSU6JRWK=
human NOS-1 cell NGTz[ndIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M4TyfGlvcGmkaYTpc44hd2ZiaIXtZY4hVk:VLUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhcWN3ME2wMlY2QTh5IN88US=> MVXTRW5ITVJ?
human KG-1 cell NVG4fYk{T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MWDJcohq[mm2aX;uJI9nKGi3bXHuJGtINTFiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1yLkexO|U2KM7:TR?= NFPHcVZUSU6JRWK=
human HT55 cell M33Hdmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NHfMPXhKdmirYnn0bY9vKG:oIHj1cYFvKEiWNUWgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlk5PzhzIN88US=> NEXlemhUSU6JRWK=
human MG-63 cell MWPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MlPuTY5pcWKrdHnvckBw\iCqdX3hckBOTy14MzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUGuNFAyPDZizszN Mlq2V2FPT0WU
human CCF-STTG1 cell MnWxS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NWTLRlhjUW6qaXLpeIlwdiCxZjDoeY1idiCFQ1[tV3RVTzFiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3Ojef-8kEBKSzVyPUGuNFQ6QDFizszN MVHTRW5ITVJ?
human RT-112 cell NV7YbI1XT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M3yxTGlvcGmkaYTpc44hd2ZiaIXtZY4hWlRvMUGyJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NU4yODN5NjFOwG0> Mn\MV2FPT0WU
human MC-IXC cell MlrNS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MWfJcohq[mm2aX;uJI9nKGi3bXHuJG1ENUm[QzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUGuNVE2OTJizszN MnnuV2FPT0WU
human HUTU-80 cell NVTlUlR5T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NUPUcG5KUW6qaXLpeIlwdiCxZjDoeY1idiCKVWTVMVgxKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OS5{OEGwN{DPxE1? NWLLVlRIW0GQR1XS
human MV-4-11 cell Mn3RS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NX7zVpRiUW6qaXLpeIlwdiCxZjDoeY1idiCPVj20MVEyKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OS5|NEWwNUDPxE1? M4PPbXNCVkeHUh?=
human LCLC-103H cell NYfs[mdKT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MmXmTY5pcWKrdHnvckBw\iCqdX3hckBNS0yFLUGwN2gh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigQ>? MX7TRW5ITVJ?
human G-401 cell Mn7CS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NH3aVZdKdmirYnn0bY9vKG:oIHj1cYFvKEdvNECxJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NU41PjR{MTFOwG0> MmTIV2FPT0WU
human A704 cell MVvHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M3uxUmlvcGmkaYTpc44hd2ZiaIXtZY4hSTdyNDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUGuOlA{OjNizszN MojFV2FPT0WU
human ESS-1 cell NHe5TlJIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NWniWoNTUW6qaXLpeIlwdiCxZjDoeY1idiCHU2OtNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVEvPjB|OU[g{txO MlrFV2FPT0WU
human HLE cell MlOwS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MYjJcohq[mm2aX;uJI9nKGi3bXHuJGhNTSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTFwNkO4NFQh|ryP Ml\IV2FPT0WU
human NY cell MUDHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MnrDTY5pcWKrdHnvckBw\iCqdX3hckBPYSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTFwOES4NlEh|ryP MlTQV2FPT0WU
human A427 cell M1[0c2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NIL6d3lKdmirYnn0bY9vKG:oIHj1cYFvKEF2MkegZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlk5ODd3IN88US=> M1XDb3NCVkeHUh?=
human SK-N-DZ cell M1i1bWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NGLmbZhKdmirYnn0bY9vKG:oIHj1cYFvKFONLV6tSHoh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0zNjB{M{ixJO69VQ>? M4CwdnNCVkeHUh?=
human J82 cell MXfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M4PK[GlvcGmkaYTpc44hd2ZiaIXtZY4hUjh{IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;Mj6wOlA5QCEQvF2= NVjS[482W0GQR1XS
human GI-1 cell NGTxUIJIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MUDJcohq[mm2aX;uJI9nKGi3bXHuJGdKNTFiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1{LkKyPVUyKM7:TR?= NHTyW5ZUSU6JRWK=
human NCI-H716 cell M1[3R2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MoXvTY5pcWKrdHnvckBw\iCqdX3hckBPS0lvSEexOkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVIvOzF4M{Og{txO NHm1V|hUSU6JRWK=
human SF126 cell MoXtS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NV7ZOlVLUW6qaXLpeIlwdiCxZjDoeY1idiCVRkGyOkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVIvPDd2NUmg{txO NYnYfVN[W0GQR1XS
human H4 cell NIjESHhIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NFn5V4tKdmirYnn0bY9vKG:oIHj1cYFvKEh2IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;Mj61NVI3OiEQvF2= MnfsV2FPT0WU
human LB831-BLC cell NXzX[4U4T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NILlRW9KdmirYnn0bY9vKG:oIHj1cYFvKEyEOEOxMWJNSyClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTJwNUS1OlYh|ryP MXfTRW5ITVJ?
human HCC1395 cell NGDxT|JIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NYXLbJBjUW6qaXLpeIlwdiCxZjDoeY1idiCKQ1OxN|k2KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Oi53OEG1OkDPxE1? MkOzV2FPT0WU
human LK-2 cell NFTkXGVIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M3rCPGlvcGmkaYTpc44hd2ZiaIXtZY4hVEtvMjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUKuOlQ2PjlizszN NHzCS2hUSU6JRWK=
human G-361 cell M4nXeWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MVvJcohq[mm2aX;uJI9nKGi3bXHuJGcuOzZzIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;Mz6wOFA5OiEQvF2= NYDzUGdMW0GQR1XS
human NCI-H2342 cell NHLG[IJIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MXjJcohq[mm2aX;uJI9nKGi3bXHuJG5EUS2KMkO0NkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NiCLQ{WwQVMvOTN|MU[g{txO MVLTRW5ITVJ?
human SK-LU-1 cell  NW[4TJRtT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NHLpT3NKdmirYnn0bY9vKG:oIHj1cYFvKFONLVzVMVEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0{NjF6N{[3JO69VQ>? M2npZnNCVkeHUh?=
human IGROV-1 cell  NWqzV2R1T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M4q1UWlvcGmkaYTpc44hd2ZiaIXtZY4hUUeUT2[tNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVMvOjR5MUOg{txO MULTRW5ITVJ?
human EB2 cell M{X1cWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NIiwUmhKdmirYnn0bY9vKG:oIHj1cYFvKEWEMjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUOuNlgyPjhizszN MkXXV2FPT0WU
human CAL-54 cell MXPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NWrWRXhoUW6qaXLpeIlwdiCxZjDoeY1idiCFQVytOVQh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0{NjJ6M{[3JO69VQ>? MX7TRW5ITVJ?
human LB1047-RCC cell NWnwUodTT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= Mo\sTY5pcWKrdHnvckBw\iCqdX3hckBQS1WELV2gZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2zMlM{OTN4ODFOwG0> NV\GfHBxW0GQR1XS
Daudi cell NWPRSlk1T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MUHJcohq[mm2aX;uJI9nKGi3bXHuJGxDOTB2Nz3SR2Mh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0{NjV|MU[0JO69VQ>? NUDYRnhWW0GQR1XS
human Daudi cell NYXKXYlCT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NVH3NGczUW6qaXLpeIlwdiCxZjDoeY1idiCGYYXkbUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVMvPjZ{MUmg{txO MWDTRW5ITVJ?
human A172 cell MUTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MnjrTY5pcWKrdHnvckBw\iCqdX3hckBCOTd{IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;Mz63N|c6KM7:TR?= NGP2c4NUSU6JRWK=
human KGN cell NUO5UHc4T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M2DWUWlvcGmkaYTpc44hd2ZiaIXtZY4hU0eQIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;ND6wOlcxQSEQvF2= NGrjNmlUSU6JRWK=
human SNG-M cell NHn1R5BIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M4XjcWlvcGmkaYTpc44hd2ZiaIXtZY4hW06JLV2gZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME20MlA5PjZ7IN88US=> M1nr[XNCVkeHUh?=
human SW1710 cell NGnV[|dIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M{nETmlvcGmkaYTpc44hd2ZiaIXtZY4hW1dzN{GwJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OE41PzNzODFOwG0> NH7tN|FUSU6JRWK=
human HT29 cells MY\Qdo9tcW[ncnH0bY9vKGG|c3H5 MmK4RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCKVEK5JINmdGy|IHnuJJNmenWvIHPvcpRicW6rbnegcYVlcXWv MXKxPFYzODN6Mh?=
human A375P cells MV;Qdo9tcW[ncnH0bY9vKGG|c3H5 NYT6UGk{SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDBN|c2WCClZXzsd{BqdiC|ZYL1cUBkd262YXnubY5oKG2nZHn1cS=> NWP5OGRbOTh4MkCzPFI>
human HN5 cells NWr2[XVRWHKxbHnm[ZJifGmxbjDhd5NigQ>? NU\PUoJJSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDIUlUh[2WubIOgbY4he2W{dX2gZ49vfGGrbnnu[{Bu\WSrdX2= MkiyNVg3OjB|OEK=
HUVEC MVPGeY5kfGmxbjDhd5NigQ>? MYixJO69VQ>? NWPpXlBNPiCq MULBcpRq[W6paX;n[Y5q[yCjY4Tpeol1gSCrbjDIWXZGSyCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKHS3YnWg[o9zdWG2aX;uJIF1KDBwMTD1UUBi\nSncjC2JIhzeyCkeTDNZZRzcWenbDDhd5NigQ>? M4\iUVI1ODN4MESy
human Daoy cell MV3Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MVPJcohq[mm2aX;uJI9nKGi3bXHuJGRid3liY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD12Lke3PVQ6KM7:TR?= M3j5TnNCVkeHUh?=
human DMS-273 cell MlPYS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NFfRNmhKdmirYnn0bY9vKG:oIHj1cYFvKESPUz2yO|Mh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF01Njl4MkCyJO69VQ>? NGP1VHRUSU6JRWK=
human KU812 cell M1fLVmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NGCyT|RKdmirYnn0bY9vKG:oIHj1cYFvKEuXOEGyJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OU4{PzhzMjFOwG0> M2PiSnNCVkeHUh?=
human NCI-H727 cell NUfYWVdUT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M2fhXWlvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLVi3Nlch[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF02NjRyOUCxJO69VQ>? NFn4e2tUSU6JRWK=
human P30-OHK cell M3uw[Wdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M2T5WmlvcGmkaYTpc44hd2ZiaIXtZY4hWDNyLV;IT{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVUvPDZ7NDFOwG0> NVnLXI5WW0GQR1XS
human MIA-PaCa-2 cell M4Xv[Gdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NXu5eGVIUW6qaXLpeIlwdiCxZjDoeY1idiCPSVGtVIFE[S1{IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;NT62NFQ3PiEQvF2= M3fqUXNCVkeHUh?=
human TT cell MoTuS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MnP1TY5pcWKrdHnvckBw\iCqdX3hckBVXCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTVwNk[yOEDPxE1? M1jNWHNCVkeHUh?=
human DK-MG cell MYXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M2DtdWlvcGmkaYTpc44hd2ZiaIXtZY4hTEtvTVegZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME21MlczODJ6IN8ccS=> M2PGSnNCVkeHUh?=

... Click to View More Cell Line Experimental Data

In vivo The mice treated with 30 mg/kg or 100 mg/kg Pazopanib reveals a significant decrease in tumor burden compared with the mice treated with vehicle or 10 mg/kg Pazopanib. Treatment with Pazopanib is well-tolerated and there is no significant difference in the body weight among the mice in each group. [2]

Protocol

Animal Research:

[2]

+ Expand
  • Animal Models: Immunodeficient mice bearing SYO-1 cells
  • Formulation: --
  • Dosages: 0 mg/kg, 10 mg/kg, 30 mg/kg, or 100 mg/kg
  • Administration: Oral administration
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 87 mg/mL warmed (198.84 mM)
Water Insoluble
Ethanol Insoluble

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 437.52
Formula

C21H23N7O2S

CAS No. 444731-52-6
Storage powder
in solvent
Synonyms GW786034

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03850730 Not yet recruiting Hereditary Hemorrhagic Telangiectasia|Epistaxis Cure HHT|University of North Carolina September 2019 Phase 1|Phase 2
NCT03850964 Not yet recruiting Hereditary Hemorrhagic Telangiectasia|Epistaxis Nosebleed|Anemia Cure HHT September 2019 Phase 2|Phase 3
NCT03850730 Not yet recruiting Hereditary Hemorrhagic Telangiectasia|Epistaxis Cure HHT|University of North Carolina September 2019 Phase 1|Phase 2
NCT03850964 Not yet recruiting Hereditary Hemorrhagic Telangiectasia|Epistaxis Nosebleed|Anemia Cure HHT September 2019 Phase 2|Phase 3
NCT03660930 Not yet recruiting Soft Tissue Sarcoma University of Washington April 1 2019 Phase 1|Phase 2
NCT03660930 Not yet recruiting Soft Tissue Sarcoma University of Washington April 1 2019 Phase 1|Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

VEGFR Signaling Pathway Map

Related VEGFR Products0

Tags: buy Pazopanib | Pazopanib supplier | purchase Pazopanib | Pazopanib cost | Pazopanib manufacturer | order Pazopanib | Pazopanib distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID